Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUSION
2022-502552-31-00Phase 2Completed
- Sponsor
- Biogen
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of biib091 in multiple sclerosis (MS) and secondary-progressive multiple sclerosis (SPMS) (2 arms), sponsored by Biogen. Primary endpoints: Number of Participants With Adverse Events (AEs), Number of Participants With Serious Adverse Events (SAEs) and 1 more. Started Aug 2023; status: completed.
02
Drugs
biib091
03
Conditions
multiple sclerosis (MS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2022-502552-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502552-31-00.